Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With SepsisGlobeNewsWire • 07/31/23
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene TherapyGlobeNewsWire • 05/31/23
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell TherapyGlobeNewsWire • 05/08/23
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell TherapyGlobeNewsWire • 04/19/23
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical TrialsAccesswire • 04/14/23
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid TumorsAccesswire • 04/12/23
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business UpdatesGlobeNewsWire • 04/04/23
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid TumorsGlobeNewsWire • 04/03/23
Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancersGlobeNewsWire • 03/20/23
Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRSGlobeNewsWire • 02/15/23
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid TumorsGlobeNewsWire • 01/25/23
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 12/05/22
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid TumorsGlobeNewsWire • 11/15/22
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022GlobeNewsWire • 09/12/22
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor CellsGlobeNewsWire • 08/29/22
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical TrialGlobeNewsWire • 08/24/22
Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/22/22
Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid TumorsGlobeNewsWire • 08/17/22
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™GlobeNewsWire • 08/03/22
